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ABSTRACT
Objective: The aim of the present study was to prepare a pantoprazole rosin complex tablet which would stabilize the drug in the mild acidic condition 
(pH 5) of the stomach during the fed state.
Methods: The method of slow solvent evaporation and antisolvent was used for the preparation of pantoprazole rosin complex.
Results: The prepared pantoprazole rosin complex exhibited decreased solubility than that of pure drug. Fourier transform infrared spectroscopy 
and differential scanning calorimetry studies confirmed the formation of a complex between the pantoprazole sodium and rosin through weak ionic 
bonds. The in vitro release studies of the pantoprazole rosin complex showed more than 80% release at the end of 90 minutes. Tablets were formulated 
using direct compression method and the prepared tablets were evaluated in vitro. The tablets were found to be within official limits with respect to 
hardness, weight variation, drug content, friability, etc.
Conclusion: The tablet formulated with croscarmellose sodium as superdisintegrant showed 97% drug release within 60 minutes. The optimized 
tablets were found to be stable in accelerated study conditions for 1 month with respect to physical characteristics and drug content. If this process 
can be scaled up to manufacturing level, this technique has the potential to develop into an invaluable technology in future.
Keywords: Pantoprazole rosin complex, Proton pump inhibitor, Croscarmellose sodium.
INTRODUCTION
Proton pump inhibitors are majorly used in the treatment of peptic 
ulcer disease, gastroesophageal reflux disease in adults and children, 
risk reduction of non-steroidal anti-inflammatory drugs-associated 
gastric ulcer, Helicobacter pylori eradication, and control of pathological 
hypersecretory conditions associated with Zollinger-Ellison 
syndrome [1], stress gastritis prophylaxis. Proton pump inhibits gastric 
secretion by binding with the H+/K+ ATPase proton pump present 
embedded at the apical membrane of the parietal cell.
The proton pump inhibitors are substituted benzimidazoles that are 
acid labile which shows poor stability at low pH. The stability of proton 
pump inhibitors decreases as pH decreases. They are stable at neutral 
and mildly acidic condition. At present, enteric coating is done to such 
acid labile drugs to prevent its degradation in the stomach. At lower pH 
levels, they become protonated and accumulate in the strongly acidic 
environment such as those found in the canaliculi of gastric cells. Here, 
these get converted to the sulfenic acid which is in equilibrium with the 
cyclic sulfonamide which binds to cysteine residues on the subunits of 
the proton pump, thereby inhibiting the secretion of gastric acid. The 
acid-catalyzed conversion of the proton pump inhibitors to activate 
sulfenamide determines the rate of inactivation of the H+/K+ ATPase 
enzyme. The acid secretion is blocked until there is de novo biosynthesis 
of a new enzyme, which usually occurs within about 96 hrs. Thus, they 
were much superior compared to H2 receptor antagonist and antacid in 
providing higher intragastric pH control [2].
Among the available proton pump inhibitors, pantoprazole has stood 
out due to the following reasons: Pantoprazole has lower pH activation 
and demonstrates greater stability than other proton pump inhibitors 
in mildly acidic conditions. Activation at lower pH makes pantoprazole 
more gastro selective. It was proved that once daily dose of 40 mg in 
the morning was effective for treating both grade 2 and more severe 
grades of erosive esophagitis (grades 3 or 4) after both 4 and 8 weeks 
of treatment. Pantoprazole shows greater efficiency than other proton 
pump inhibitor and H2 receptor antagonist. Pantoprazole also exhibits 
safety and tolerability in many patients [3].
Pantoprazole sodium sesquihydrate (PSS) is chemically known as 




PSS was obtained from RA Chem Pharma Ltd, Hyderabad. All other 




Preparation of pantoprazole rosin complex
The method of slow solvent evaporation and antisolvent was used for 
the preparation of pantoprazole rosin complex. Methanol and ethanol 
were considered for the study since both rosin and drug were soluble 
in alcohol. Both water and n-hexane were tested as antisolvent. It was 
found that water is a suitable antisolvent and formed pantoprazole 
rosin complex. Thus, water was considered for further studies.
Specific amount of pantoprazole sodium and rosin was dissolved 
in 10 ml of ethanol using magnetic stirrer at 400 rpm taken in a 50 ml 
beaker. The solvent was allowed to be evaporated until it formed a 
viscous supersaturated solution. The specific amount of water was 
added as antisolvent to this while raising the rpm of the magnetic 
stirrer to 900 rpm. The solution was allowed to mix for 3 minutes. 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Pantoprazole rosin complex precipitated out as a white precipitate. The 
solution was filtered using Whatman filter paper and allowed to dry in 
open air [5].
Optimization of pantoprazole rosin complex
The ratio of drug: Rosin is varied to determine the optimized 
pantoprazole rosin complex formation as shown in Table 1. In the case 
of pantoprazole sodium, rosin 1:2, an attempt was made to stabilize or 
overcome the gummy nature of rosin gum using magnesium stearate as 
stabilizer and lubricant [6].
Determination of practical yield
The pantoprazole rosin complex obtained after the addition of 
antisolvent was allowed to mix for 3 minutes. Then, it was filtered 
through 41 μm Whatman filter paper and allowed to dry in open. The 
practical yield was measured after overnight drying for 12 hrs.
Determination of drug content
A dose of 10 mg of pantoprazole rosin complex was weighed accurately 
and transferred to 100 ml volumetric flask containing 75 ml of distilled 
water, shaken for few minutes and the volume was made up to mark 
with distilled water. It was sonicated for 8 minutes and the solution was 
passed through Whatman filter paper 41 μm. The filtrate was checked 
for absorbance at 289 nm [7].
Characterization of pantoprazole rosin complex by differential 
scanning calorimetry (DSC) and Fourier transform infrared 
spectroscopy (FTIR)
DSC
DSC was performed using DSC-60, Shimadzu, Japan. The samples were 
scanned at a rate of 5°C/minutes from 25°C to 250°C.
Infrared spectroscopy
Infrared spectroscopy was conducted using a Shimadzu FTIR 8300 
spectrophotometer, and the spectrum was recorded in the region of 
4000-400/cm.
Physical stability testing of pantoprazole rosin complex in 
different pH
Quantity equivalent to 10 mg of pure pantoprazole sodium was 
accurately weighed and transferred to 10 ml test tubes. The stability 
of pantoprazole rosin complex was performed at different pH in 0.1M 
hydrochloric acid (pH 1.2), phosphate buffer pH 5, pH 6.8, and pH 7.4. 
The result was compared with pure pantoprazole sodium in the 
same solvent. Studies were observed for 90 minutes. The observation 
was noted at time intervals 0th, 5th, 10th, 15th, 30th, 45th, 60th, and 
90th minutes [8].
Formulation of the tablet using pantoprazole rosin complex
Pantoprazole sodium tablet was prepared using 10 station automatic 
tablet compression machine (Rimek Mini Press 1). The excipients were 
selected based on direct compressibility of pantoprazole sodium [9]. 
Formula for pantoprazole rosin complex tablet is shown in Table 2.
Procedure of preparation of tablets by direct compression
The ingredients except for drug rosin complex were mixed in the 
descending order of weights, followed by the addition of drug rosin 
complex. Then blending was done for 10 minutes. And then, the blend 
was transferred through sieve #44. After sieving, blend required for 
each tablet was weighed individually and punching of tablets was 
performed using the Manual Tablet Compaction Machine (hydraulic 
pump mechanism).
Analysis of pre-compression blend and tablets
Pre-compression blends were tested for angle of repose, compressibility 
index, and Hausner ratio. Compressed tablets were evaluated for weight 
variation, friability, and hardness as per the standard procedure.
Disintegration test
The time required for the tablet to disintegrate and pass 
through 2.0±0.2 mm mesh of the disintegration apparatus was noted as 
per the systematic procedure [10].
Assay
Five tablets were randomly selected and powdered. A volume of 10 mg 
of the powder was weighed and transferred to a 100 ml volumetric 
flask and dissolved in 75 ml of distilled water. The solution was then 
sonicated in a bath sonicator for 8 minutes. The solution was then made 
up to the mark with distilled water. Then, the solution was filtered 
through Whatman filter paper (41 μm). The filtrate was analyzed by UV 
spectrophotometry at 289 nm against water as blank.
In vitro release studies: Dissolution testing
The in vitro drug release studies for the prepared formulation were 
conducted for 2 hrs using an electrolab model dissolution tester USP 
type - I apparatus (rotating paddle), set at 100 rpm and a temperature 
of 37±0.5°C with 900 ml of the pH5 phosphate buffer as medium. At 
specified intervals, 2 mL samples were withdrawn from the dissolution 
medium and replaced with fresh medium to keep the volume constant. 
The absorbance of the sample solution was analyzed at 289 nm for the 
presence of the model drug, using a UV-visible spectrophotometer [11].
Selection of dissolution media was based on the stability testing 
performed for both pantoprazole and pantoprazole rosin complex 
at different pH. The pH 5 dissolution media was selected considering 
the fact that it represents the stomach condition during fed state and 
dissolution medium volume was set at 900 ml to suit the fed stomach 
condition.
Stability studies on optimized tablets
Stability studies were performed on optimized tablets, according to 
the guidelines by ICH at accelerated study conditions (30±2°C and 
65±5% RH). The study was conducted for the duration of 1 month. 
Tablets were wrapped with aluminum foil (primary packing) and were 
placed inside a plastic container. The samples were taken out on the 
30th day and were evaluated for release profiles [12].
RESULTS AND DISCUSSION
Optimization of pantoprazole rosin complex
It was observed that best result was obtained when drug-rosin 
ratio was 1:1. When the drug-rosin ratio was increased to 1:2, the 
complexation reaction was incomplete due to overall greater cohesive 
and gummy nature of the rosin gum. Reduction of the drug-rosin ratio 
to 1:0.5, the viscous supersaturated state was not observed as seen with 
1:1 drug-rosin ratio.
Determination of percentage yield
The practical yield obtained was better with drug: rosin ratio 1:1 than 
other ratios.
Determination of drug content
When the solution was sonicated, it was found that some particles 
remained undissolved and were separated by filtration through 
Whatman filter paper 41 μm. It was assumed that this undissolved 
particle was the rosin component of pantoprazole rosin complex. Thus, 
when the filtrate was scanned from 400 nm to 200 nm, the spectra 
of filtrate and the pure pantoprazole sodium were found to be same. 
Thus, assuming the concept that the bond between pantoprazole and 
rosin component was temporary and it is sufficient to pass through the 
stomach membrane and get absorbed due to the lipophilic nature of the 
rosin gum. It was found that 13 mg of pantoprazole rosin complex was 
equivalent to 10 mg of pantoprazole sodium.
Table 1: Optimization of pantoprazole rosin complex
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Characterization of pantoprazole rosin complex with DSC and FTIR
DSC
Shift in the peak from 155.14°C to 128.88°C (Figs. 1 and 2) indicated 
that physical complexation between pantoprazole sodium and rosin 
was through weaker ionic bonds.
FTIR spectra
Results from the FTIR spectra of drug: Rosin complex indicated that 
pantoprazole rosin complex retained most of the major peaks as seen 
in FTIR spectra of pure pantoprazole sodium (Figs. 3-5). Further 
confirming the possibility that physical complexation occurs between the 
pantoprazole sodium and rosin particle. FTIR spectra of optimized final 
formulation and pantoprazole rosin complex were found to be similar.
Physical stability testing of pantoprazole rosin complex in 
different pH (Fig. 6)
0.1M hydrochloric acid pH 1.2
Stability testing in 0.1 M hydrochloric acid showed that it failed to 
stabilize the pantoprazole rosin complex and yellow color was obtained 
immediately after 5 minutes.
Phosphate buffer pH 5
Solution changed to yellow color after 30 minutes when stability testing 
was performed in phosphate buffer pH 5 (moderate acidic condition), 
it was found that the pantoprazole rosin complex was able to stabilize 
the drug to some extent.
Phosphate buffer pH 7.4
No color change was observed in phosphate buffer pH 6.8 and pH 7.4 even 
after 90th minute indicating the drug complex is stable in both the solution.
Pre-compression parameters of blends F1-F10
Angle of repose for different batches varies from 28.70° to 32.30° which 
indicates good to passable flow property. Compressibility index for all 
batches found to be <12.81, and Hausner ratio is <1.15 indicating good 
flow property and compressibility.
Weight variation and friability test
Weight variation test results varied from lowermost 199.54±0.42 mg to 
maximum 200.83±0.92 mg for batches F1-F10. Friability test values for 
all formulations were within the limits with maximum value of 0.25%.
Disintegration test
All the formulations showed disintegration time within the limit for 
conventional tablets.
Assay
Drug content for all the batches was found to be within the limit as 
shown in Table 3.
In vitro dissolution study
Table 4 depicts the dissolution profiles of F1-F10 batches of 
pantoprazole rosin complex tablets.
Formulation batches F1-F5 were prepared using different diluents 
and 5% sodium starch glycolate as superdisintegrant. By interpreting 
the dissolution profile, compressibility property, and appearance, 
Avicel (F4 formulation) was selected as the suitable diluent 
for future batches of tablet. Batches F4, F6, and F7 had similar 
composition and only superdisintegrant varied. Formulations F6 and 
F7 had shown better drug release profile at 45th minutes with 5% 
crospovidone and 5% croscarmellose sodium as superdisintegrant, 
respectively. Considering dissolution data of formulations F8-F10 
with superdisintegrant 2.5% crospovidone, 2.5% croscarmellose, and 
3.75% croscarmellose, respectively, it was observed that best release 
profile, i.e. 95% at the end of 30 minutes was obtained with 2.5% 
croscarmellose sodium (F9). Therefore, the released pantoprazole-
rosin (95% by 30 minutes) from F9 formulation will be stable at 
fed state of stomach as per stability study conducted at different pH 
Table 2: Formulae for pantoprazole rosin complex tablets
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Pantoprazole rosin complex (mg) 26 26 26 26 26 26 26 26 26 26
Microcrystalline cellulose (mg) 154 - - - - - - - - -
Ethyl cellulose (mg) - 154 - - - - - - - -
Directly compressible lactose (mg) - - 154 - 77 - - - - -
Avicel 112 (mg) - - - 154 77 154 154 159 159 157
Sodium starch glycolate (mg) 10 10 10 10 10 - - - - -
Crospovidone (mg) - - - - - 10 - 5 - 7
Croscarmellose sodium (mg) - - - - - - 10 - 5 -
Poly vinyl pyrrolidine 40 K (mg) 5 5 5 5 5 5 5 5 5 5
Magnesium stearate (mg) 2 2 2 2 2 2 2 2 2 2
Talc (mg) 3 3 3 3 3 3 3 3 3 3
Total (mg) 200 200 200 200 200 200 200 200 200 200
Fig. 1: Differential scanning calorimetry thermogram of 
pantoprazole sodium
Fig. 2: Differential scanning calorimetry thermogram of 
pantoprazole rosin complex
91
Asian J Pharm Clin Res, Vol 10, Issue 5, 2017, 88-92
 Aravind et al. 
Fig. 3: Fourier transform infrared spectroscopy spectrum of pantoprazole sodium
Fig. 4: Fourier transform infrared spectroscopy spectrum of pantoprazole rosin complex
Fig. 5: Fourier transform infrared spectroscopy spectrum of optimized formulation F9
Fig. 6: Physical stability testing of pantoprazole rosin complex in 
0.1 M hydrochloric acid pH 1.2 and in phosphate buffer pH 5
values. Faster absorption might be observed due to increase in the 
lipophilicity of the complex.
Stability studies on optimized tablets
The result obtained were found to be similar to that of original 
preparation and shown to be stable as shown in Table 5. Hence, this 
formulation can be considered for future study.
CONCLUSION
The present study demonstrated the successful preparation of 
pantoprazole-rosin complex and its direct compression into tablets. The 
methods adopted involved slow solvent evaporation and antisolvent 
addition for the preparation of pantoprazole rosin complex. If this 
process can be scaled up to manufacturing level, this technique has the 
potential to develop into an invaluable technology in future.
Table 3: Assay of batches F1-F10
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